Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519076 | 0.81 | GSK3B (0.53) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL29955313 | 0.77 | AHR (0.45) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL29363263 | 0.76 | GSK3B (0.49) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL1093112 | 0.76 | CDK1 (0.51) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL29953709 | 0.76 | CDK1 (0.51) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL29378092 | 0.76 | HPGD (0.61) | AHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL5780430 | 0.76 | AHR (0.47) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL248974 | 0.76 | HPGD (0.61) | AHRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL18132168 | 0.76 | AHR (0.47) | AHRMEN1KMT2AMAPTKIF11 | |
| SCHEMBL16431539 | 0.76 | AHR (0.47) | AHRMEN1KMT2AMAPTKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215106-B1 | INDOLE GRAFTED SOLID SUPPORT FOR FMOC-SOLID PHASE PEPTIDE SYNTHESIS | MALLINCKRODT LLC (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2215106-A1 | INDOLE GRAFTED SOLID SUPPORT FOR FMOC-SOLID PHASE PEPTIDE SYNTHESIS | Mallinckrodt Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7714063-B2 | Solid support for Fmoc-solid phase synthesis of peptides | MALLINCKRODT INC. (US) | 2010-05-11 | — | — | US | disclosed |
| WO-2009064637-A1 | INDOLE GRAFTED SOLID SUPPORT FOR FMOC-SOLID PHASE PEPTIDE SYNTHESIS | MALLINCKRODT INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131587-A1 | Solid Support for Fmoc-Solid Phase Synthesis of Peptides | MALLINCKRODT INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131587-A1 | Solid Support for Fmoc-Solid Phase Synthesis of Peptides | MAX, PTMS, ANPEP | AHR 4055/4885MEN1 1350/4885KMT2A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.